RxDoctor Payments Data

Stefany Andujo

Family · El Paso, TXNPI 1487122487

Payments from drug & device makers

$1,891in general payments, 2019–2025

Across 20 payments — averaging $94.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$325
  • Medtronic$199
  • AstraZeneca$192
  • Amgen$150
  • Boston Scientific$144
  • Corcept Therapeutics$143
  • plus $738 from 7 others

What the payments were for

  • Food & beverage$1,891100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,891 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$9,954
Medicare patients
70
Services billed
1,106

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin169$249,675
OzempicSemaglutide25$48,864
MounjaroTirzepatide22$34,687
JanuviaSitagliptin Phosphate16$23,004
MyrbetriqMirabegron15$14,862
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$4,181
Gabapentin104$2,001
Atorvastatin Calcium194$1,384
Albuterol Sulfate HfaAlbuterol Sulfate38$1,153
Omeprazole56$1,105
Levothyroxine Sodium128$1,056
Lisinopril100$743
Metformin Hcl103$658
Tamsulosin Hcl65$650
Montelukast Sodium82$630

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$325$249,675169 claims
Novo NordiskOzempic$121$48,86425 claims
Lilly USA, LLCMounjaro$122$34,68722 claims
Astellas Pharma US IncMyrbetriq$83$14,86215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →